Measles virus hijacks stem cells to attack ovarian cancer
NCT ID NCT02068794
First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 4 times
Summary
This early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will deliver the virus directly to cancer cells, killing them. The study involves 34 participants and aims to find the safest dose and see if it helps control the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cells infected with a modified measles virus (MV-NIS)
- What this could lead to
- If it works, this could point toward a new treatment option for recurrent ovarian cancer that is hard to treat with standard therapies.
- What could go wrong
- This is an early-phase trial with only 34 participants, so it may not work for everyone. The virus and stem cells could cause side effects, and the treatment is still experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target Hard-to-Treat ovarian cancers?
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches